Related Experiment Video
Updated: Jan 3, 2026

Isolation of Fidelity Variants of RNA Viruses and Characterization of Virus Mutation Frequency
Published on: June 16, 2011
Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and
Adil Mohamed1, Derek R Clements2, Shashi A Gujar2,3
1Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Abstract:
Little is known about how genetic variations in viruses affect their success as therapeutic agents. The type 3 Dearing strain of Mammalian orthoreovirus (T3D) is undergoing clinical trials as an oncolytic virotherapy. Worldwide, studies on reovirus oncolysis use T3D stocks propagated in different laboratories. Here, we report that genetic diversification among T3D stocks from various sources extensively impacts oncolytic activity. The T3D strain from the Patrick Lee laboratory strain (TD3PL) showed significantly stronger oncolytic activities in a murine model of melanoma than the strain from the Terence Dermody laboratory (T3DTD). Overall in vitro replication and cytolytic properties of T3D laboratory strains were assessed by measuring virus plaque size on a panel of human and mouse tumor cells, and results were found to correlate with in vivo oncolytic potency in a melanoma model. T3DPL produced larger plaques than T3DTD and than the T3D strain from the ATCC (T3DATCC) and from the Kevin Coombs laboratory (T3DKC). Reassortant and reverse genetics analyses were used to decipher key genes and polymorphisms that govern enhanced plaque size of T3DPL Five single amino acid changes in the S4, M1, and L3 genome segments of reovirus were each partially correlated with plaque size and when combined were able to fully account for differences between T3DPL and T3DTD Moreover, polymorphisms were discovered in T3DTD that promoted virus replication and spread in tumors, and a new T3DPL/T3DTD hybrid was generated with enhanced plaque size compared to that of T3DPL Altogether, single amino acid changes acquired during laboratory virus propagation can have a large impact on reovirus therapeutic potency and warrant consideration as possible confounding variables between studies.IMPORTANCE The reovirus serotype 3 Dearing (T3D) strain is in clinical trials for cancer therapy. We find that closely related laboratory strains of T3D exhibit large differences in their abilities to replicate in cancer cells in vitro, which correlates with oncolytic activity in a in a murine model of melanoma. The study reveals that five single amino acid changes among three reovirus genes strongly impact reovirus therapeutic potency. In general, the findings suggest that attention should be given to genomic divergence of virus strains during research and optimization for cancer therapy.
Insights
Genetic variations in Mammalian orthoreovirus (T3D) strains significantly impact oncolytic therapy effectiveness. Laboratory-acquired genetic changes in T3D influence viral replication and therapeutic potency in cancer treatment.
Area of Science:
- Virology
- Oncolytic Virotherapy
- Molecular Biology
Background:
- Mammalian orthoreovirus (T3D) is under investigation as an oncolytic virotherapy for cancer.
- Studies on T3D efficacy often use virus stocks from different laboratories, raising questions about strain consistency.
Purpose of the Study:
- To investigate how genetic variations among different T3D laboratory strains affect their oncolytic activity.
- To identify specific genetic changes responsible for differences in viral potency.
Main Methods:
- Assessed in vitro replication and cytolytic properties by measuring virus plaque size on tumor cells.
- Utilized reassortant and reverse genetics analyses to pinpoint key genes and polymorphisms.
- Evaluated in vivo oncolytic activity in a murine melanoma model.
Main Results:
- Significant differences in oncolytic activity were observed between T3D strains from different laboratories (e.g., T3DPL vs. T3DTD).
- In vitro plaque size correlated with in vivo oncolytic potency.
- Five single amino acid changes in S4, M1, and L3 genome segments were identified as key contributors to differences in plaque size and potency.
Conclusions:
- Genetic diversification of T3D strains during laboratory propagation can substantially alter their therapeutic efficacy.
- Attention to genomic divergence among virus strains is crucial for consistent research and optimization of reovirus-based cancer therapies.
Related Concept Videos
Viral Mutations
Viral Recombination
Leaky Scanning

